---
title: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870974/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: In patients with resectable NSCLC, perioperative durvalumab
  plus neoadjuvant chemotherapy was associated with significantly greater event-free
  survival and pathological complete response than neoadjuvant chemotherapy alone,
  with a safety profile that was consistent with the individual agents. (Funded by
  AstraZeneca; AEGEAN ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with resectable NSCLC, perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (Funded by AstraZeneca; AEGEAN ClinicalTrials.gov number, ...